TorqueGlide | Topical solution for migraine support and pain relief
-
Product Info
TorqueGlide™
Advanced Neurological Support & Pain Relief
- Immediate and long-lasting support for migraine attacks
- Powerful relief for joint and muscle pain
- Potent blend of research-backed ingredients
- Analgesic and anti-inflammatory properties
- Effective antioxidant action
- Reduces CGRP levels for migraine relief
- Combats acne and assists with skin aging
- Neuroprotective qualities
- Decreases C-reactive protein levels
- Reduces frequency of chronic cluster headaches
- Addresses neuropathic and orofacial pain
- May reduce neuro-inflammation
POWERFUL TOPICAL RELIEF
TorqueGlide combines research-backed natural and patented ingredients including menthol, curcumin, and boswellia to provide neurological support when massaged onto affected areas.
PRECISION ROLLERBALL APPLICATION
The cooling rollerball tip glides smoothly over skin for direct absorption of active ingredients, providing an immediate cooling sensation for additional relief.
NON-GREASY FORMULA
The fast-absorbing gel formula applies cleanly without leaving residue and won't stain clothing, making it perfect for on-the-go use.
SCIENCE-BACKED INGREDIENTS
TorqueGlide's pain-relieving ingredients are supported by studies showing anti-inflammatory, analgesic, and antioxidant properties.
VERSATILE PAIN RELIEF
Suitable for migraine, arthritis, cramps, back pain and more, providing natural relief for both acute and chronic conditions.
ALL-NATURAL FORMULATION
Contains menthol, curcumin, boswellia, yerba mate, helichrysum oil and other natural extracts to reduce inflammation and fight pain through multiple mechanisms.
* These statements have not been evaluated by the FDA. TorqueGlide is not intended to diagnose, treat, cure, or prevent any disease. Always consult with your healthcare professional before starting any new regimen.
Wed, Apr 23, 25
Effectiveness and Tolerability of Atogepant (Qulipta) in the Prevention of Migraine
STAR study shows atogepant (Qulipta) effectively reduces migraine days by 56.6% in real-world clinical practice, even for patients with previous treatment failures. Learn about this breakthrough.
Read MoreWed, Apr 23, 25
Impact of Visual Stimulus Complexity on Associative Learning in Migraine Patients
Groundbreaking research reveals how migraine patients process visual information differently. This 2025 study found that migraine patients take longer to process simple visual stimuli compared to complex images, which is...
Read MoreSat, Apr 19, 25
FDA Authorizes First Digital Therapeutic for Migraine
In a development for migraine patients, the FDA has granted marketing authorization to CT-132, making it the first prescription digital therapeutic specifically designed for the preventive treatment of episodic migraine...
Read More